Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Stroke. 2012 Jul 12;43(9):2300–2306. doi: 10.1161/STROKEAHA.112.657411

Figure 2.

Figure 2

Concentrations of CX3CL1 over the course of 180 days after stroke onset in patients with poor outcome compared to those without poor outcome (based on mRS, GOSE and SIS). *P<0.05 and **P<0.01 unadjusted for initial stroke severity (Mann-Whitney U test). (After controlling for initial stroke severity using the NIHSS score, the P value for CX3CL1 and mRS = 0.155, GOSE = 0.046 and SIS = 0.022; controlling for initial stroke severity using infarct volume, the P value for CX3CL1 and mRS = 0.132, GOSE = 0.015 and SIS = 0.014.)